GLIPR1-ΔTM synergizes with docetaxel in cell death and suppresses resistance to docetaxel in prostate cancer cells

Conclusions:
Our data suggested that addition of GLIPR1-ΔTM treatment in PCa cells increases the efficacy of docetaxel and may inhibit the emergence of drug resistance; potentially permitting a decrease of docetaxel dose for patients with mCRPC eliminating its systemic toxicities.

Source: Molecular Cancer - June 19, 2015 Category: Cancer & Oncology Authors: Styliani KaranikaTheodoros KarantanosShinji KurosakaJianxiang WangTakahiro HirayamaGuang YangSanghee ParkAlexei GolstovRyuta TanimotoLikun LiTimothy Thompson Source Type: research